Immunotherapy Medicine Nivolumab Opens a New Door for AIDS Treatment

Given nivolumab, a new-generation cancer medicine, a patient diagnosed with both lung cancer and AIDSwas shown to have a reduced amount of HIV virus in their cells and an increased immune response.
Cancer immunotherapy medicine nivolumab (Opdivo) reduced the reservoir of dormant HIV cells in the body and increased the patient’s immune response, offering new hope for people living with HIV.
The findings concern a man who had been living with HIV since 1995 and was treated for lung cancer at age 51. This patient, whose lung cancer recurred less than six months after surgery and first-line chemotherapy, was subsequently given nivolumab.
The patient was then shown to have a dramatic reduction in reservoirs of HIV-infected cells and increased activity of CD8-positive “killer” T cells, an important immune system cell type.
New-generation immunotherapies such as nivolumab, called immune checkpoint inhibitors, block the action of cell-surface molecules that cause the immune system to perceive diseased, damaged or foreign cells as friendly.
The immunotherapy medicine, on HIV-infected white blood cells lying in reservoirs throughout the body without producing HIV, appears to have a “wake-up” effect. Dormant immune system cells carrying HIV are not attacked by antiretroviral therapy, the standard treatment for AIDS, or by the immune system. However, if they reactivate and start producing HIV, they may become targets for AIDS medicines and the normal immune system.
The use of certain medicines that reactivate dormant HIV-carrying cells was already being investigated. If HIV reservoirs are cleared of dormant infected cells, patients with AIDS could potentially be cured.
However, this study should not be interpreted as “a cancer medicine has ended AIDS” . Larger randomized studies are needed to determine whether this or similar anticancer medicines will have a substantial effect on HIV reservoirs. Nevertheless, this study has provided valuable information for better understanding the immune system and both diseases.
Article photograph: An electron microscope image showing HIV infection (yellow) of an immune system T cell (blue).
Sources
Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer.
J Thorac Dis. 2017 Jun.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.